<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043975</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-7CR</org_study_id>
    <nct_id>NCT04043975</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan</brief_title>
  <official_title>Japanese Prospective Real World Registry of Nivolumab Plus Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma (ARCC) Categorized Into IMDC Intermediate/Poor Risks (J-ENCORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, descriptive study of renal cell cancer patients who are
      treated with the combination of nivolumab plus ipilimumab as first line of systematic therapy
      in the real world setting in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of starting nivolumab plus ipilimumab to the date of death from any cause. (Up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From date of starting nivolumab plus ipilimumab to the first date of documented progression, as determined by the investigators (as per RECIST 1.1 criteria), or death due to any cause, whichever occurs first. (Up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor response over time</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From first documentation of tumor response after the date of starting nivolumab plus ipilimumab to disease progression or death due to any cause, whichever occurs first. (Up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quality of life by National Comprehensive Cancer Network/ Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) v2.0</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>During the observation period or until 100 days after discontinuation of dosing with nivolumab and ipilimumab (Up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR on subsequent therapy</measure>
    <time_frame>From initiation of a second line of therapy after discontinuation of first line nivolumab+ipilimumab treatment (Up to 3 years)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Advanced or Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic RCC</arm_group_label>
    <description>Patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) with intermediate or poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, who will be treated with Nivolumab + Ipilimumab for the first time</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes adult (≧ 20 years) Japanese patients with histological
        confirmation of advanced or metastatic renal cell carcinoma (aRCC) and International
        Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk category Intermediate/Poor
        who will be treated with the combination of nivolumab+ipilimumab as first line of
        systematic therapy in the real world setting.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of Renal Cell Carcinoma (RCC)

          -  No prior systemic therapy for RCC

          -  RCC patients who are anticipated to start treatment with nivolumab and ipilimumab
             regimen in the timeframe between after IRB approval to enrollment-end date

          -  IMDC risk category Intermediate/Poor

          -  ≧ 20 years old patients for whom informed consent was obtained from the patient at the
             time of this study participation

        Exclusion Criteria:

          -  Patients who are enrolled in a post marketing safety study on nivolumab plus
             ipilimumab combination therapy in Japan

          -  Pregnant and/or lactating women

          -  Patients who are judged to be inappropriate by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokyo</city>
        <zip>1070052</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

